Terakubo S, Takemura H, Yamamoto H, Ikejima H, Kunishima H, Kanemitsu K, Kaku M, Shimada J
Department of Microbiology, St. Marianna University School of Medicine, Sugao, Miyamae, Kawasaki, Kanagawa 216-8511, Japan.
J Infect Chemother. 2001 Dec;7(4):263-6. doi: 10.1007/s101560170025.
The in-vitro antimicrobial activity of everninomicin, a novel oligosaccharide antibiotic, was tested against clinical isolates of 11 methicillin-susceptible Staphylococcus aureus (MSSA) strains, 11 methicillin-resistant S. aureus (MRSA) strains, 22 Staphylococcus epidermidis strains, 23 Enterococcus faecalis strains, 23 Enterococcus faecium strains, 23 Enterococcus avium strains, 27 Streptococcus pneumoniae strains, 22 Streptococcus pyogenes strains, and 20 Streptococcus agalactiae strains. The minimum inhibitory concentrations (MICs) of everninomicin were determined by Etest and compared with those of vancomycin, teicoplanin, and minocycline. The Etest showed that everninomicin exhibited excellent activity (MIC, <0.016 to 1.5 microg/ml) against the gram-positive cocci tested. The antimicrobial activity of everninomicin against S. aureus and S. epidermidis was stronger than that of vancomycin, teicoplanin, and minocycline, in particular against MRSA, with an MIC50 of 0.38 microg/ml and an MIC90 of 0.5 microg/ml. Against strains of enterococci and streptococci, everninomicin was more active than vancomycin, but as active as teicoplanin.
新型寡糖抗生素埃维霉素的体外抗菌活性针对11株甲氧西林敏感金黄色葡萄球菌（MSSA）、11株耐甲氧西林金黄色葡萄球菌（MRSA）、22株表皮葡萄球菌、23株粪肠球菌、23株屎肠球菌、23株鸟肠球菌、27株肺炎链球菌、22株化脓性链球菌和20株无乳链球菌的临床分离株进行了测试。通过Etest法测定了埃维霉素的最低抑菌浓度（MIC），并与万古霉素、替考拉宁和米诺环素的最低抑菌浓度进行了比较。Etest法显示，埃维霉素对所测试的革兰氏阳性球菌表现出优异的活性（MIC，<0.016至1.5微克/毫升）。埃维霉素对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性强于万古霉素、替考拉宁和米诺环素，尤其是对MRSA，其MIC50为0.38微克/毫升，MIC90为0.5微克/毫升。对于肠球菌和链球菌菌株，埃维霉素比万古霉素更具活性，但与替考拉宁活性相当。
